Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 1;7(5):e2413172.
doi: 10.1001/jamanetworkopen.2024.13172.

GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes

Duy Do  1 , Tiffany Lee  1 , Samuel K Peasah  2 , Chester B Good  2 , Angela Inneh  1 , Urvashi Patel  1
Affiliations

GLP-1 Receptor Agonist Discontinuation Among Patients With Obesity and/or Type 2 Diabetes

Duy Do et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cohort study examines the prevalence of and factors associated with glucagon-like peptide 1 agonist discontinuation among new users.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Peasah and Good reported receiving research support for their organization from Evernorth outside the submitted work. No other disclosures were reported.

References

    1. Marso SP, Daniels GH, Brown-Frandsen K, et al. ; LEADER Steering Committee; LEADER Trial Investigators . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827 - DOI - PMC - PubMed
    1. Lundgren JR, Janus C, Jensen SBK, et al. . Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med. 2021;384(18):1719-1730. doi:10.1056/NEJMoa2028198 - DOI - PubMed
    1. Weiss T, Yang L, Carr RD, et al. . Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK. BMJ Open Diabetes Res Care. 2022;10(1):e002517. doi:10.1136/bmjdrc-2021-002517 - DOI - PMC - PubMed

Publication types

Substances